Vaccination Against SARS-CoV-2 in Lung Transplant Recipients: Immunogenicity, Efficacy and Safety

Lung transplant (LuTx) recipients are considered to be at higher risk of developing serious illness from COVID-19. COVID-19 vaccines were shown in randomized clinical trials to substantially reduce the severity of COVID-19, however, patients receiving immunosuppressants were excluded from these tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Svorcova, Monika, Novysedlak, Rene, Lischke, Robert, Vachtenheim, Jiri, Strizova, Zuzana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198330/
https://www.ncbi.nlm.nih.gov/pubmed/35720376
http://dx.doi.org/10.3389/fimmu.2022.906225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198330/
https://www.ncbi.nlm.nih.gov/pubmed/35720376
http://dx.doi.org/10.3389/fimmu.2022.906225

Ejemplares similares